The No. 1 Trade Show Site in the U.S.

Menu
×
EVENT DATE
Apr 2016
M T W T F S S
252627282930
EXPO DATE
Apr 2016
M T W T F S S
252627282930

Venue


Online Event
Location map
Tel:
Type: Online Event

HOTEL DEALS

Booking.com

TRAVEL DEALS

Expedia.com

Partners

exhibitus success by design Remington Hotels

Assessing Cognitive Safety of Drugs in Clinical Development

B2B

EVENT DESCRIPTION

Spend 60 minutes with two industry experts and walk away with a firm understanding of why there is a need to assess cognitive safety in clinical development of compounds, the methodological considerations for cognitive assessment in clinical trials, approaches to the analysis and interpretation of cognitive outcome measures and how current state-of-the-art cognitive assessment technology can be incorporated into the clinical development process to facilitate early decision making, evaluate cognitive efficacy, profile safety and tolerability and satisfy regulatory requirements in an increasingly challenging and competitive pharmaceutical landscape.

Importance for Drug Development: The presenters will discuss why the accurate measurement of specific aspects of cognitive function is essential for the evaluation of the efficacy of new medications being developed to treat some of our most feared and devastating medical conditions such as Alzheimer’s disease, depression, schizophrenia and ADHD. Recognizing that the ability to test, measure and monitor cognitive performance over time introduces the opportunity for patients to be identified earlier and more accurately, the evaluation of new treatments faster and more efficiently, and to improve decision making throughout the development process.

Value Across the Drug Development Cycle for All Therapies: Any drug that crosses the blood-brain barrier (BBB) can produce cognitive effects that can interfere with everyday functioning. Importantly, this includes drugs for both CNS and non-CNS indications (e.g. cardiovascular drugs; including statins, diabetes, oncology, HIV, pain, antihistamines, anticonvulsants and antimuscarinics). The presenters will explore strategies for measuring cognitive function during clinical drug development for all therapies and how this can help determine dose-response relationships, provide competitive differentiation, detect off-target pharmacological effects and assess the risk/benefit profiles.

Review of Methodologies, Study Design and Analysis: Learn how when assessing cognitive safety in a clinical trial, one also has to be aware of basic methodological principles, including study design and statistical analysis, from Phase I through to postmarketing as well as how best to interpret the magnitude of any identified effects, including comparison with benchmarks.

Don't wait to register for the Assessing Cognitive Safety of Drugs in Clinical Development. You'll meet influential people and maximize your opportunities for success. Start now by accessing the information below.

EVENT CONTACTS

Sign Up for FREE Membership and Log In to access Event Contact Information.

EVENT DETAILS

Primary Industry:
Clinical Pharmacology
Other Industries:
Clinical Pharmacology, Professional Healthcare
Audience:
This webinar is designed for pharmaceutical and biotech research professionals, particularly those involved in clinical development of both CNS and non-CNS compounds. This includes therapeutic area leaders, clinical project and program leaders for compounds, clinical development scientists, operational scientists, project managers and those involved in medical oversight and monitoring or pharmacovigilance.
Notes:
Show Owner:
Sponsorship:

Exhibitor Information +

Booth Details:

Booth Size
Booth Cost
No exhibiting.
Amenities
Electricity:
n/a
Water:
n/a
Generator:
n/a
Marketing Vehicles Allowed:
n/a
Services
n/a

floor plan

MORE events +

BUSINESS+
HEALTH CARE+
MANUFACTURING+
TECHNOLOGY+

Display Makers

Promo Makers

2017: 2,575 Trade Shows
2018: 575 Trade Shows
© copyright since 2008 All Rights Reserved eventsinamerica.com
1,020
page views